HeXun Biosciences Co (6986) Fair Value & Analysis
Healthcare · TW · Market cap 2.3B TWD
Fair value as of: Jul 23, 2026
From 24 valuation models · updated 18 days ago
Fair value updated Jul 23, 2026, revised from 47.15 TWD to 51.72 TWD (+9.7%) since Jul 12, 2026. Share price −5.3% over the past month.
A solid business, screening 16% undervalued on our models.
What matters now
- A fairly wide model range (33.00 TWD to 64.96 TWD) leaves room in how you read the outcome.
- Our model range runs from 33.00 TWD (bear) to 64.96 TWD (bull), base 51.72 TWD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 61/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 23, 2026.
How to read this chart
8‑month range 43.55 TWD – 70.00 TWD · fair‑value band 33.00 TWD – 64.96 TWD · the 44.50 TWD price screens below the 51.72 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Jul 23, 2026.
Analysis
HeXun Biosciences Co (6986) currently trades at 44.50 TWD, while our model-based Fair Value estimate is 51.72 TWD, implying the stock looks roughly 16.2% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, HeXun Biosciences Co generated revenue of 293M TWD at a net margin of 38.2%. Revenue grew 2.9% year over year. It earns a return on equity of 16.4%. The balance sheet holds a net cash position of 166M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 33.00 TWD (bear case) to 64.96 TWD (bull case); at 44.50 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 16%, 6986 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (96.81 TWD) versus Asset-Based (9.53 TWD). Highest evidence: Growth DCF (80).
Notify me when 6986 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
HeXun Biosciences Co reported revenue of 293M TWD in FY2025 versus 0 TWD in FY2021. Reported net income was 112M TWD in FY2025.
Watch 6986: get an alert when its fair value changes →
Peer Group
Biotechnology · 606 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare HeXun Biosciences Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is HeXun Biosciences Co (6986) overvalued or undervalued?
What is the fair value of 6986?
What is the quality score of 6986?
What is the revenue of HeXun Biosciences Co (6986)?
What is the net profit margin of 6986?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track HeXun Biosciences Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.